FL-MITSUBISHI-POWER
23.6.2022 15:07:13 CEST | Business Wire | Press release
Renewable energy developer Ion Renewables, Ltd. (ION Renewables) has signed an exclusivity agreement with Mitsubishi Power Americas, Inc. (Mitsubishi Power) for four battery energy storage system (BESS) projects using Mitsubishi Power’s Emerald storage solutions totaling 185.5 megawatt (MW) / 371 megawatt-hours (MWh) in Ireland. These projects will provide Secure, Sustainable Electricity System (DS3) energy storage and system services including fast frequency and capacity response to Ireland’s National Grid, enabling the addition of more renewable energy. All four projects will be located at brownfield sites with existing electrical interconnects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622006036/en/
In addition to providing frequency response to the National Grid, the BESS projects will support three major energy initiative programs for Ireland and the European Union:
- Ireland’s Climate Action Plan to reach net-zero greenhouse gas emissions no later than 2050
- EirGrid Group’s DS3 program that addresses the challenges of integrating world-leading levels of renewable generation into the grid and targets having 70% of Ireland’s electricity come from renewables by 2030
- REPowerEU’s draft directive, which seeks to eliminate imported gas by 2030 and diversify energy sources
“We are delighted to be working with the Mitsubishi Power team to deliver these important projects,” said John Ward, Director, ION Renewables. “These installations represent a viable and economical solution to balance the network, strongly aligning with the principles of the REPowerEU draft directive. These projects demonstrate that effective solutions for storing energy can be achieved by utilizing renewable power that would otherwise be curtailed.”
Scheduled to come online in 2024, the four BESS projects will be Mitsubishi Power’s first in Europe, bringing the total global deployment of its Emerald storage solutions to more than 2 gigawatt-hours (GWh).
Mitsubishi Power’s Emerald storage solutions for Ion Renewables include project engineering, equipment supply, and a 10-year long-term service agreement.
According to Tom Cornell, Senior Vice President, Energy Storage Solutions, Mitsubishi Power Americas, these projects emphasize the importance of BESS adoption as a viable solution with more countries striving to meet their climate action goals. “Bringing our Emerald storage solutions to Ireland and working with Ion Renewables is an exciting moment for us. The continued adoption of battery storage technologies outside of the United States and the recognition of the important role they play in enabling renewable energy generation to reach net-zero cannot be overstated. Mitsubishi Power’s Emerald storage solutions will help Ireland reach its goal of 70% generation from renewable sources while ensuring the stability of the grid with a secure power system.”
Read more about some of Mitsubishi Power’s BESS projects:
- Innergex Orders Mitsubishi Power Emerald Storage Solution to Bring 425 Megawatt-hours of Battery Storage to Chile
- San Diego Gas & Electric Orders Mitsubishi Power Emerald Storage Solution to Add Capacity for High Energy Demand
- Mitsubishi Power and Powin Partner to Enhance California’s Grid Reliability with Two Battery Energy Storage Projects
- MHPS Will Supply Battery Energy Storage Systems to Help Balance the California Grid
- Key Capture Energy, Mitsubishi Hitachi Power Systems, and Powin Energy Partner to Add 200 MW of Battery Storage to the Texas Grid
About Mitsubishi Power Americas, Inc.
Mitsubishi Power Americas, Inc. (Mitsubishi Power) headquartered in Lake Mary, Florida, employs more than 2,300 power generation, energy storage, and digital solutions experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity throughout North, Central, and South America. Mitsubishi Power’s power generation solutions include gas, steam, and aero-derivative turbines; power trains and power islands; geothermal systems; PV solar project development; environmental controls; and services. Energy storage solutions include green hydrogen, battery energy storage systems, and services. Mitsubishi Power also offers intelligent solutions that use artificial intelligence to enable autonomous operation of power plants. Mitsubishi Power is a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI). Headquartered in Tokyo, Japan, MHI is one of the world’s leading heavy machinery manufacturers with engineering and manufacturing businesses spanning energy, infrastructure, transport, aerospace, and defense. For more information, visit the Mitsubishi Power Americas website and follow us on LinkedIn .
About Ion Renewables, Ltd.
Ion Renewables, Ltd. (ION Renewables) was formed by top experts in the energy storage industry with the goal of deploying energy storage to provide grid balancing and renewables integration. We are developing and advising on projects in Ireland and worldwide through our network. In this current batch of projects in Ireland, ION Renewables is developing ESS facilities at large industrial load centres, providing rapid deployment and low environmental footprint on existing brownfield sites. These projects will assist in balancing the network by providing additional functionality to the grid to enable the further deployment of renewables and ultimately reduce Ireland's dependency on imported fossil fuels. For more information, visit the ION Renewables website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622006036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom